Therapeutic Innovations for Targeting Childhood Neuroblastoma: Implications of the Neurokinin-1 Receptor System

Neuroblastoma is the most common solid extracranial malignant tumor in children. Despite recent advances in the treatment of this heterogenous tumor with surgery and chemotherapy, the prognosis in advanced stages remains poor. Interestingly, neuroblastoma is one of the few solid tumors, to date, in...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2017-11, Vol.37 (11), p.5911-5918
Main Authors: Berger, Michael, VON Schweinitz, Dietrich
Format: Article
Language:English
Subjects:
Antineoplastic Agents - pharmacology
Child
Humans
Immunotherapy
Molecular Targeted Therapy
Neuroblastoma - immunology
Neuroblastoma - therapy
Receptors, Neurokinin-1 - chemistry
Receptors, Neurokinin-1 - immunology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Neuroblastoma is the most common solid extracranial malignant tumor in children. Despite recent advances in the treatment of this heterogenous tumor with surgery and chemotherapy, the prognosis in advanced stages remains poor. Interestingly, neuroblastoma is one of the few solid tumors, to date, in which an effect for targeted immunotherapy has been proven in controlled clinical trials, giving hope for further advances in the treatment of this and other tumors by targeted therapy. A large array of novel therapeutic options for targeted therapy of neuroblastoma is on the horizon. To this repεrtoirε, the neurokinin-1 receptor (NK1R) system was recently added. The present article explores the most recent developments in targeting neuroblastoma cells via the NK1R and how this new knowledge could be helpful to create new anticancer therapies agains neuroblastoma and other cancers.
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.12037